You are here

  • Home
  • Archive
  • Volume 21, Issue 7
  • Extended-Field Irradiation and Intracavitary Brachytherapy Combined With Cisplatin and Amifostine for Cervical Cancer With Positive Para-Aortic or High Common Iliac Lymph Nodes: Results of Arm II of Radiation Therapy Oncology Group (RTOG) 0116

Article Text

Article menu
Download PDFPDF
Cervical Cancer
Extended-Field Irradiation and Intracavitary Brachytherapy Combined With Cisplatin and Amifostine for Cervical Cancer With Positive Para-Aortic or High Common Iliac Lymph Nodes: Results of Arm II of Radiation Therapy Oncology Group (RTOG) 0116
  1. Jr William Small, MD*,
  2. Kathryn Winter, MS†,
  3. Charles Levenback, MD‡,
  4. Revathy Iyer, MD‡,
  5. Sharon R. Hymes, MD‡,
  6. Anuja Jhingran, MD‡,
  7. David Gaffney, MD§,
  8. Beth Erickson, MD∥ and
  9. Kathy Greven, MD
  1. *The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL;
  2. †RTOG Statistical Center, Philadelphia, PA;
  3. ‡MD Anderson Cancer Center, Houston, TX;
  4. §University of Utah, Salt Lake City, UT;
  5. ∥Medical College of Wisconsin, Milwaukee, WI; and
  6. Wake Forest University, Winston Salem, NC.
  1. Address correspondence and reprint requests to William Small Jr, MD, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 251 E. Huron St, Chicago, IL. E-mail: wsmall{at}nmff.org.

Abstract

Objectives: Radiation Therapy Oncology Group (RTOG) 0116 was designed to test the ability of amifostine (Ethyol; MedImmune LLC, Gaithersburg, MD), a cytoprotective agent, to reduce the acute toxicity of combined therapy with extended-field irradiation, brachytherapy, and cisplatin chemotherapy in patients with cervical cancer with para-aortic or high common iliac disease. This report presents the results of part 2.

Materials and Methods: Radiation Therapy Oncology Group 0116 was a 2-part trial. Part 1 delivered extended-field irradiation, brachytherapy, and cisplatin; part 2 added amifostine and required 16 evaluable patients to assess an improved toxicity profile. Eligibility included evidence for high common iliac or para-aortic metastasis. Patients were treated for a total dose of 45 Gy in 25 fractions with intracavitary irradiation. Intensity-modulated radiation therapy was not allowed. The final point A dose was 85 Gy low-dose rate equivalent. High-dose rate techniques were allowed. The positive para-aortic and iliac nodes were to be boosted to 54 to 59.4 Gy. Amifostine at 500 mg was to be delivered with every fraction of radiotherapy.

Results: The study opened on August 1, 2001, and closed March 3, 2007, after accruing 45 patients, 18 for the second part with amifostine. This analysis reports the primary end point for the patients entered on part 2 of the study. Three patients were excluded, one was ineligible, and 2 withdrew. The median follow-up was 22.9 months (range, 6.5-45.4 months). The median dose of amifostine delivered was 5000 mg (range, 500-13,500 mg). Thirteen patients (87%) experienced an acute grade 3/4 toxicity (excluding grade 3 leukopenia). This compared to an 81% rate in part 1 of the trial. The estimated median survival was 34.8 months with a 20% late grade 3/4 toxicity rate.

Conclusions: Amifostine, as delivered in this study, did not reduce acute toxicity in this patient population.

  • Cervical cancer
  • Extended-field radiotherapy
  • Chemoradiation
  • Toxicity
  • Amifostine

https://doi.org/10.1097/IGC.0b013e31822c2769

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Presented at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA, October 2007.

    • This work was supported by RTOG U10 CA21661 and CCOP U10 CA37422 NCI grants.

    • The authors have no conflicts of interests to disclose.